~~<i id='BA5DEE583A'><strike id='BA5DEE583A'><tt id='BA5DEE583A'><pre id='BA5DEE583A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：Wikipedia 2025-10-02 21:07:36 - browse：4543

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Rare Northern Lights show in US this week: Where and how to see it

explore

knowledge

entertainment

explore

focus

TOLGAAKMEN/AFP/GettyImagesThisyearcouldshapeuptobeahistoriconefortobaccocontrol—oroneinwhichBigTobac

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Second House panel advances two

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Sen. Bill Cassidy on how to lower drug prices

leisure time

fashion

explore

Alkermes shareholders re

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Wildfire smoke exposes gaps in outdoor worker protections

Anxious about a speech? A startup wants you to pop a minty cardiac drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

When prostate cancer spreads, where it goes matters

As demand for Covid shots wanes, Moderna seeks its next success

The PBM ad wars are taking over Washington, D.C.

Malaria cases in Florida and Texas: Here’s what you need to know

With fresh data, a dynamic duo powers Eli Lilly to new heights

knowledge

Drinking water from half of US faucets contains PFAS: Study

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Second House panel advances two

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Neutralizing antibodies against HIV shows promise in children

FDA approves Leqembi, a milestone in Alzheimer’s treatment

knowledge

entertainment

explore

focus